GlassScriptPhysician profile
Marc Irwin Sharfman
NPI 1750376364
$200,678.55
in general payments reported to CMS, 2019-2025
16 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $15K · 2021: $29K · 2022: $50K · 2023: $18K · 2024: $13K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $2,566 · Travel and Lodging: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,987.50 |
| Food and Beverage | $2,565.52 |
| Travel and Lodging | $2,098.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95,514.65 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $74,250.08 | 2019-2022 | |
| Allergan, INC. | $12,438.03 | 2020-2021 | |
| Lilly USA, LLC | $9,475.95 | 2019-2024 | Emgality |
| Teva Pharmaceuticals USA, INC. | $7,391.50 | 2019-2023 | Ajovy |
| Avanir Pharmaceuticals, INC. | $770.00 | 2019 | |
| Pfizer INC. | $323.56 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $144.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $102.42 | 2022 | |
| Bausch Health US, LLC | $61.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.88 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $47.19 | 2019-2020 | |
| Assertio Therapeutics, INC. | $32.13 | 2019-2020 | |
| Axsome Therapeutics, INC. | $28.32 | 2025 | Symbravo |
| Impel Pharmaceuticals LLC | $23.60 | 2025 | Trudhesa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $19.63 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Sharfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.